{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:59:04Z","timestamp":1793372344274,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Cholera remains a significant public health challenge in Zambia, particularly in the Copperbelt Province, where antibiotic-resistant\n                      <jats:italic>Vibrio cholerae<\/jats:italic>\n                      strains are increasingly threatening treatment efficacy. This study aimed to determine the prevalence of cholera and the antibiotic resistance patterns of\n                      <jats:italic>V. cholerae<\/jats:italic>\n                      isolates at three tertiary hospitals in the region.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cross-sectional study was conducted across three major referral hospitals in the Copperbelt Province (Arthur Davison Children\u2019s Hospital, Kitwe Teaching Hospital, and Ndola Teaching Hospital) during the cholera outbreak from January to April 2024. Clinical samples from suspected cholera cases were analysed, and antimicrobial susceptibility testing was performed following Clinical Laboratory Standards Institute guidelines and the European committee on antimicrobial susceptibility testing methodology for\n                      <jats:italic>Vibrio cholerae<\/jats:italic>\n                      . To isolate\n                      <jats:italic>Vibrio cholerae<\/jats:italic>\n                      , alkaline peptone water and thiosulfate-citrate-bile salt-sucrose agar were utilized. The isolates were identified based on colony morphology, Gram staining, biochemical testing, and serotyping. Antimicrobial susceptibility testing was conducted by using the Kirby-Bauer disk diffusion method. Descriptive statistics were employed to assess the prevalence of\n                      <jats:italic>Vibrio cholerae<\/jats:italic>\n                      , and chi-square tests were applied with\n                      <jats:italic>p<\/jats:italic>\n                      -values of &lt;\u20090.05 indicating statistical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 892 suspected cases, 334 (37.4%) were confirmed as\n                      <jats:italic>V. cholerae<\/jats:italic>\n                      through culture. The highest number of\n                      <jats:italic>V. cholerae<\/jats:italic>\n                      confirmed cases was recorded at Ndola Teaching Hospital 221 (24.8%), followed by Kitwe Teaching Hospital 88 (9.9%), while Arthur Davison Children\u2019s Hospital 25 (2.8%) reported the lowest. High antimicrobial resistance was observed trimethoprim\/sulfamethoxazole 69 (74.2%), ampicillin 75 (54.3%), and imipenem 22 (46.8%). In contrast, erythromycin 25 (100%), gentamicin 6 (85.7%) and ciprofloxacin 118 (76.6%) remained highly effective. The overall prevalence of multidrug resistance (MDR) in\n                      <jats:italic>Vibrio cholerae<\/jats:italic>\n                      was 3.7%. Among these, resistance to four or more antibiotics was observed in 3 (1.2%), followed by resistance to the combination of Ciprofloxacin, Ceftazidime, and Tetracycline in 2 (0.8%). All other MDR patterns were detected in a single isolate each (0.4%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The high prevalence of antibiotic-resistant\n                      <jats:italic>Vibrio cholerae<\/jats:italic>\n                      in the Copperbelt Province underscores the urgent need for enhanced antimicrobial stewardship and robust surveillance systems to inform effective cholera control strategies. Sustainable public health impact can be achieved through targeted immunization campaigns in endemic areas combined with strengthened water, sanitation, and hygiene (WASH) interventions, including improved access to clean water, adequate sanitation infrastructure, hygiene promotion, and supportive policies, which are essential for reducing transmission and preventing future outbreaks in vulnerable populations. However, because the number of antibiotics used in antimicrobial susceptibility testing across isolates varies, these results should be interpreted cautiously. Such differences may affect the comparability and overall interpretation of resistance patterns.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11259-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:29:45Z","timestamp":1751362185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Emerging antibiotic resistance in Vibrio cholerae: a study of cholera prevalence and resistance patterns in Zambia\u2019s Copperbelt Province"],"prefix":"10.1186","volume":"25","author":[{"given":"David","family":"Chisompola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nzobokela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Moono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"Chinyante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Chipipa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Chapuswike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Chakopo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nswana","family":"Mukuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Chakulya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"11259_CR1","doi-asserted-by":"publisher","unstructured":"Chowdhury F, Ross AG, Islam MT, McMillan NAJ, Qadri F, Diagnosis. Management, and Future Control of Cholera. Clin Microbiol Rev. 2022;35. Available from: https:\/\/doi.org\/10.1128\/cmr.00211-21.","DOI":"10.1128\/cmr.00211-21"},{"key":"11259_CR2","doi-asserted-by":"publisher","first-page":"100295","DOI":"10.1016\/j.puhip.2022.100295","volume":"4","author":"SS Musa","year":"2022","unstructured":"Musa SS, Ezie KN, Scott GY, Shallangwa MM, Ibrahim AM, Olajide TN, et al. The challenges of addressing the cholera outbreak in Cameroon. Public Health Pract. 2022;4:100295.","journal-title":"Public Health Pract"},{"key":"11259_CR3","unstructured":"WHO. Data show marked increase in annual cholera deaths. World Health Organ WHOn. 2024;481\u201395."},{"key":"11259_CR4","doi-asserted-by":"publisher","first-page":"e0008227","DOI":"10.1371\/journal.pntd.0008227","volume":"14","author":"J Mwaba","year":"2020","unstructured":"Mwaba J, Debes AK, Shea P, Mukonka V, Chewe O, Chisenga C, et al. Identification of cholera hotspots in zambia: A Spatiotemporal analysis of cholera data from 2008 to 2017. Akullian A, editor. PLoS Negl Trop Dis. 2020;14:e0008227.","journal-title":"PLoS Negl Trop Dis"},{"key":"11259_CR5","doi-asserted-by":"publisher","first-page":"e0000163","DOI":"10.1371\/journal.pwat.0000163","volume":"2","author":"PW Gething","year":"2023","unstructured":"Gething PW, Ayling S, Mugabi J, Muximpua OD, Kagulura SS, Joseph G. M Jeuland editor 2023 Cholera risk in lusaka: A Geospatial analysis to inform improved water and sanitation provision. PLOS Water 2 e0000163.","journal-title":"PLOS Water"},{"key":"11259_CR6","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.2166\/wh.2024.094","volume":"22","author":"BH Gulumbe","year":"2024","unstructured":"Gulumbe BH, Chishimba K, Shehu A, Chibwe M. Zambia\u2019s battle against cholera outbreaks and the path to public health resilience: a narrative review. J Water Health. 2024;22:2257\u201375.","journal-title":"J Water Health"},{"key":"11259_CR7","unstructured":"Ministry of Health Zambia. National Daily Cholera Update. 2024; Available from: https:\/\/www.facebook.com\/share\/p\/18ZZbsGwja\/. Cited 2025 Mar 11."},{"key":"11259_CR8","doi-asserted-by":"publisher","first-page":"A83","DOI":"10.1016\/j.vaccine.2019.06.031","volume":"38","author":"B Das","year":"2020","unstructured":"Das B, Verma J, Kumar P, Ghosh A, Ramamurthy T. Antibiotic resistance in Vibrio cholerae: Understanding the ecology of resistance genes and mechanisms. Vaccine. 2020;38:A83\u201392.","journal-title":"Vaccine"},{"issue":"4","key":"11259_CR9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.4269\/ajtmh.24-0558","volume":"112","author":"TM Phiri","year":"2025","unstructured":"Phiri TM, Imamura T, Mwansa PC, Mathews I, Mtine F, Chanda J, et al. Increased prevalence of antimicrobial resistance in Vibrio cholerae in the capital and provincial areas of zambia, January 2023\u2013February 2024. Am J Trop Med Hyg. 2025;112(4):845\u20138. https:\/\/doi.org\/10.4269\/ajtmh.24-0558.","journal-title":"Am J Trop Med Hyg."},{"key":"11259_CR10","unstructured":"Ministry of Health Zambia. National Integrated Cholera Surveillance, Laboratory and case Management Guidelines. 2024. Available from: https:\/\/w2.znphi.co.zm\/wp-content\/uploads\/filr\/7009\/Cholera%20Surveillance%20and%20Case%20Management%20Guidelines_2024.pdf.\u00a0Cited 2025 Apr 22."},{"key":"11259_CR11","doi-asserted-by":"publisher","unstructured":"Shah MM, Bundi M, Kathiiko C, Guyo S, Galata A, Miringu G, et al. Antibiotic-Resistant Vibrio cholerae O1 and its SXT elements associated with two cholera epidemics in Kenya in 2007 to 2010 and 2015 to 2016. Microbiol Spectr. 2023;11(3):e04140-22. https:\/\/doi.org\/10.1128\/spectrum.04140-22.","DOI":"10.1128\/spectrum.04140-22"},{"key":"11259_CR12","first-page":"A73","volume":"38","author":"T Ramamurthy","year":"2020","unstructured":"Ramamurthy T, Das B, Chakraborty S, Mukhopadhyay AK, Sack DA. Diagnostic techniques for rapid detection of Vibrio cholerae O1\/O139. Cholera Control Three Cont Vaccines Antibiot WASH. 2020;38:A73\u201382.","journal-title":"Cholera Control Three Cont Vaccines Antibiot WASH"},{"key":"11259_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1186\/s12879-020-05454-0","volume":"20","author":"C Williams","year":"2020","unstructured":"Williams C, Cumming O, Grignard L, Rumedeka BB, Saidi JM, Grint D, et al. Prevalence and diversity of enteric pathogens among cholera treatment centre patients with acute diarrhea in uvira, Democratic Republic of congo. BMC Infect Dis. 2020;20:741.","journal-title":"BMC Infect Dis"},{"key":"11259_CR14","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1186\/s12889-024-19621-4","volume":"24","author":"A Bitew","year":"2024","unstructured":"Bitew A, Gelaw A, Wondimeneh Y, Ayenew Z, Getie M, Tafere W, et al. Prevalence and antimicrobial susceptibility pattern of Vibrio cholerae isolates from cholera outbreak sites in Ethiopia. BMC Public Health. 2024;24:2071.","journal-title":"BMC Public Health"},{"key":"11259_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12879-019-3714-z","volume":"19","author":"D Abana","year":"2019","unstructured":"Abana D, Gyamfi E, Dogbe M, Opoku G, Opare D, Boateng G, et al. Investigating the virulence genes and antibiotic susceptibility patterns of Vibrio cholerae O1 in environmental and clinical isolates in accra, Ghana. BMC Infect Dis. 2019;19:76.","journal-title":"BMC Infect Dis"},{"key":"11259_CR16","doi-asserted-by":"crossref","unstructured":"Karatuna O, Matuschek E, \u00c5hman J, Caidi H, Kahlmeter G. Vibrio species: development of EUCAST susceptibility testing methods and MIC and zone diameter distributions on which to determine clinical breakpoints. J Antimicrob Chemother. 2024;79:375\u201382.","DOI":"10.1093\/jac\/dkad391"},{"key":"11259_CR17","unstructured":"Clinical and Laboratory Standards Institute (CLSI). M45 Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. 3rd ed. Wayne, PA; 2018."},{"key":"11259_CR18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4269\/ajtmh.20-0058","volume":"103","author":"I Parvin","year":"2020","unstructured":"Parvin I, Shahunja KM, Khan SH, Alam T, Shahrin L, Ackhter MM, et al. Changing susceptibility pattern of Vibrio cholerae O1 isolates to commonly used antibiotics in the largest diarrheal disease hospital in Bangladesh during 2000\u20132018. Am J Trop Med Hyg. 2020;103:652\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"11259_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13756-016-0122-7","volume":"5","author":"PK Gupta","year":"2016","unstructured":"Gupta PK, Pant ND, Bhandari R, Shrestha P. Cholera outbreak caused by drug resistant Vibrio cholerae serogroup O1 biotype ElTor serotype Ogawa in nepal; a cross-sectional study. Antimicrob Resist Infect Control. 2016;5:23.","journal-title":"Antimicrob Resist Infect Control"},{"key":"11259_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12879-017-2232-0","volume":"17","author":"H Chiyangi","year":"2017","unstructured":"Chiyangi H, Muma JB, Malama S, Manyahi J, Abade A, Kwenda G, et al. Identification and antimicrobial resistance patterns of bacterial enteropathogens from children aged 0\u201359 months at the university teaching hospital, lusaka, zambia: a prospective cross sectional study. BMC Infect Dis. 2017;17:117.","journal-title":"BMC Infect Dis"},{"key":"11259_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12879-025-10683-2","volume":"25","author":"S Kerketta","year":"2025","unstructured":"Kerketta S, Rout UK, Kshatri JS, Kerketta AS, Paikaray AK, Dash A, et al. An acute diarrheal disease outbreak in urban setting of odisha, India. BMC Infect Dis. 2025;25:283.","journal-title":"BMC Infect Dis"},{"key":"11259_CR22","doi-asserted-by":"publisher","first-page":"e0181496","DOI":"10.1371\/journal.pone.0181496","volume":"12","author":"LC Dengo-Baloi","year":"2017","unstructured":"Dengo-Baloi LC, Sem\u00e1-Baltazar CA, Manhique LV, Chitio JE, Inguane DL, Langa JP. Antibiotics resistance in El Tor vibrio cholerae 01 isolated during cholera outbreaks in Mozambique from 2012 to 2015. PLoS ONE. 2017;12:e0181496.","journal-title":"PLoS ONE"},{"key":"11259_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13756-022-01100-3","volume":"11","author":"X Yuan","year":"2022","unstructured":"Yuan X, Li Y, Vaziri AZ, Kaviar VH, Jin Y, Jin Y, et al. Global status of antimicrobial resistance among environmental isolates of Vibrio cholerae O1\/O139: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2022;11:62.","journal-title":"Antimicrob Resist Infect Control"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11259-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11259-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11259-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:29:47Z","timestamp":1751362187000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11259-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11259"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11259-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6266244\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the Mulungushi University School of Medicine and Health Sciences Research Committee Board (IRB: 00012281, FWA: 0002888; Reference No. SMHS-MU1-2025-28) and the National Health Research Authority, Zambia (NHRA8108\/25\/02\/2025) on February 25, 2025. Written informed consent was waived due to the retrospective nature of the study and the minimal risk posed to participants. To ensure confidentiality, patient information was anonymized, and all data were encrypted using encryption within the data collection and analysis tool. Access to the data was strictly restricted to the study authors through password-protected systems and minimizing the risk of unauthorized access or disclosure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"879"}}